These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25237156)

  • 21. Colistin induced acute kidney injury in critically ill children: a prospective study utilizing RIFLE criteria.
    Meysam S; Khosravi Z; Rashti R; Qorbani M; Assadi F; Hayatshahi A; Parin T; Faghihi T
    Daru; 2022 Jun; 30(1):11-15. PubMed ID: 34807396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.
    Hassan MM; Gaifer Z; Al-Zakwani IS
    Int J Clin Pharm; 2018 Apr; 40(2):444-449. PubMed ID: 29542034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymyxin B and colistin-the economic burden of nephrotoxicity against multidrug resistant bacteria.
    Tuon FF; Rocha JL; Gasparetto J
    J Med Econ; 2019 Feb; 22(2):158-162. PubMed ID: 30466325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Truong CB; Durham SH; Qian J
    Expert Opin Drug Saf; 2021 May; 20(5):603-609. PubMed ID: 33573405
    [No Abstract]   [Full Text] [Related]  

  • 25. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers.
    Keirstead ND; Wagoner MP; Bentley P; Blais M; Brown C; Cheatham L; Ciaccio P; Dragan Y; Ferguson D; Fikes J; Galvin M; Gupta A; Hale M; Johnson N; Luo W; McGrath F; Pietras M; Price S; Sathe AG; Sasaki JC; Snow D; Walsky RL; Kern G
    Toxicol Sci; 2014 Feb; 137(2):278-91. PubMed ID: 24189134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.
    Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM
    Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z; Danziger L
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics and risk factors of colistin-induced nephrotoxicity.
    Kim J; Lee KH; Yoo S; Pai H
    Int J Antimicrob Agents; 2009 Nov; 34(5):434-8. PubMed ID: 19726164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and Risk Factors for Colistin-Associated Nephrotoxicity.
    Temocin F; Erdinc S; Tulek N; Demirelli M; Bulut C; Ertem G
    Jpn J Infect Dis; 2015; 68(4):318-20. PubMed ID: 25720641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.
    Pogue JM; Lee J; Marchaim D; Yee V; Zhao JJ; Chopra T; Lephart P; Kaye KS
    Clin Infect Dis; 2011 Nov; 53(9):879-84. PubMed ID: 21900484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between colistin dose and development of nephrotoxicity.
    Lee YJ; Wi YM; Kwon YJ; Kim SR; Chang SH; Cho S
    Crit Care Med; 2015 Jun; 43(6):1187-93. PubMed ID: 25756417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
    John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients.
    Gauthier TP; Wolowich WR; Reddy A; Cano E; Abbo L; Smith LB
    Antimicrob Agents Chemother; 2012 May; 56(5):2392-6. PubMed ID: 22371891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of Nephrotoxicity Associated With Nonrenally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing.
    Maniara BP; Healy LE; Doan TL
    J Pharm Pract; 2020 Jun; 33(3):287-292. PubMed ID: 30253682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery.
    Gomes EC; Falci DR; Bergo P; Zavascki AP; Rigatto MH
    Int J Antimicrob Agents; 2018 Jul; 52(1):86-89. PubMed ID: 29501603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colistin-induced Nephrotoxicity in a Tertiary Teaching Hospital.
    Al-Abdulkarim DA; Alzuwayed OA; Al Ammari M; Al Halwan S; Al Maklafi N; Thomas A
    Saudi J Kidney Dis Transpl; 2020; 31(5):1057-1061. PubMed ID: 33229769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia.
    Korkmaz Ekren P; Töreyin ZN; Berk Takır H; Kalamanoğlu Balcı M; Gaygısız Ü; Gürsel G; Ergan B; Yalçın A; Saltürk C; Aydoğdu M; Ergün R; Güven P; Ulubay G; Gürün Kaya A; Çeltik A; Uluer H; Bacakoğlu F; Sayıner A
    Tuberk Toraks; 2017 Dec; 65(4):271-281. PubMed ID: 29631525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.
    Phe K; Shields RK; Tverdek FP; Aitken SL; Guervil DJ; Lam WM; Musgrove RJ; Luce AM; Tam VH
    J Antimicrob Chemother; 2016 Dec; 71(12):3585-3587. PubMed ID: 27543655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colistin-associated nephrotoxicity among patients in intensive care units (ICU) of hospitals in Selangor.
    Rashizal Sazli MR; Syed Mohamed AF; Wan Mazuan WM; Ling SM; Mahmud A; Amin Nordin S
    Med J Malaysia; 2017 Apr; 72(2):100-105. PubMed ID: 28473672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colistin nephrotoxicity in critically ill patients after implementation of a new dosing strategy.
    Ozel AS; Ergönül Ö; Korten V
    J Infect Dev Ctries; 2019 Oct; 13(10):877-885. PubMed ID: 32084017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.